Literature DB >> 23430821

Enzyme replacement therapy and extended newborn screening for mucopolysaccharidoses: opinions of treating physicians.

David J Coman1, Ian M Hayes, Veronica Collins, Margaret Sahhar, J Ed Wraith, Martin B Delatycki.   

Abstract

We conducted a survey of physician opinions in relation to enzyme replacement therapy (ERT) and extended newborn screening (ENBS) for mucopolysaccharidoses (MPS). A questionnaire consisting of hypothetical clinical scenarios about ERT and ENBS for MPS was posted on metab-L, a list server for the metabolic community. The questionnaire included similar questions to those used in previous studies that sought the views of individuals and families affected by MPS. Our aim was to compare medical professionals' opinions with that of the individuals and families affected by MPS that they serve. The questionnaire was completed by 35 physicians, most of whom were metabolic physicians. Responses differed significantly between the physician and parent groups when the clinical scenario involved intellectual impairment. In this setting, physicians were significantly less inclined to advocate the use of ERT. Comparison of the responses to the ENBS scenarios revealed that compared to physicians, family of individuals with MPS were more inclined to desire diagnosis at birth, even if no treatment could alter the outcome of the condition. Compared to the family of individuals with MPS, physicians are more likely to advocate the use of ERT and ENBS where there is proven medical benefit to the affected individual.

Entities:  

Year:  2011        PMID: 23430821      PMCID: PMC3509829          DOI: 10.1007/8904_2011_9

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  25 in total

1.  Quality of life assessment: The world health organization perspective.

Authors:  S Saxena; J Orley
Journal:  Eur Psychiatry       Date:  1997       Impact factor: 5.361

2.  Newborn screening for Duchenne muscular dystrophy: a psychosocial study.

Authors:  E P Parsons; A J Clarke; K Hood; E Lycett; D M Bradley
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-03       Impact factor: 5.747

Review 3.  Enzyme replacement therapy for the mucopolysaccharide storage disorders.

Authors:  Emil D Kakkis
Journal:  Expert Opin Investig Drugs       Date:  2002-05       Impact factor: 6.206

4.  Subject and observer-rated quality of life in schizophrenia.

Authors:  P B Fitzgerald; C L Williams; N Corteling; S L Filia; K Brewer; A Adams; A R de Castella; T Rolfe; P Davey; J Kulkarni
Journal:  Acta Psychiatr Scand       Date:  2001-05       Impact factor: 6.392

5.  Perception of quality of life by patients, partners and treating physicians.

Authors:  K A Wilson; A J Dowling; M Abdolell; I F Tannock
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

6.  Enzyme-replacement therapy in mucopolysaccharidosis I.

Authors:  E D Kakkis; J Muenzer; G E Tiller; L Waber; J Belmont; M Passage; B Izykowski; J Phillips; R Doroshow; I Walot; R Hoft; E F Neufeld
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

7.  Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders.

Authors:  Victor R De Jesus; X Kate Zhang; Joan Keutzer; Olaf A Bodamer; Adolf Mühl; Joseph J Orsini; Michele Caggana; Robert F Vogt; W Harry Hannon
Journal:  Clin Chem       Date:  2008-11-06       Impact factor: 8.327

8.  Determinants of discordance between patients and physicians in their assessment of lupus disease activity.

Authors:  Jim C Yen; Michal Abrahamowicz; Patricia L Dobkin; Ann E Clarke; Renaldo N Battista; Paul R Fortin
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

9.  Psychosocial correlates of patient-physician discordance in inflammatory bowel disease.

Authors:  Maida J Sewitch; Michal Abrahamowicz; Alain Bitton; Donald Daly; Gary E Wild; Albert Cohen; Saul Katz; Peter L Szego; Patricia L Dobkin
Journal:  Am J Gastroenterol       Date:  2002-09       Impact factor: 10.864

10.  Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

Authors:  James E Wraith; Lorne A Clarke; Michael Beck; Edwin H Kolodny; Gregory M Pastores; Joseph Muenzer; David M Rapoport; Kenneth I Berger; Stuart J Swiedler; Emil D Kakkis; Tanja Braakman; Elenie Chadbourne; Karen Walton-Bowen; Gerald F Cox
Journal:  J Pediatr       Date:  2004-05       Impact factor: 4.406

View more
  1 in total

1.  Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.

Authors:  Mehmet Umut Akyol; Tord D Alden; Hernan Amartino; Jane Ashworth; Kumar Belani; Kenneth I Berger; Andrea Borgo; Elizabeth Braunlin; Yoshikatsu Eto; Jeffrey I Gold; Andrea Jester; Simon A Jones; Cengiz Karsli; William Mackenzie; Diane Ruschel Marinho; Andrew McFadyen; Jim McGill; John J Mitchell; Joseph Muenzer; Torayuki Okuyama; Paul J Orchard; Bob Stevens; Sophie Thomas; Robert Walker; Robert Wynn; Roberto Giugliani; Paul Harmatz; Christian Hendriksz; Maurizio Scarpa
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.